INTRODUCING NOBIVAC EDGE™ VACCINES

FULL SIZE PROTECTION, HALF SIZE VACCINES

Choose the best protection for your clients with convenient small dose options that deliver powerful protection for dogs of all sizes.

Nobivac EDGE™ LEPTO4

The first and only 0.5 mL leptospirosis vaccine shown to be effective against disease, mortality and shedding for dogs of all sizes.

DELIVERS 4-WAYLEPTOSPIROSIS PROTECTION

  • Shown to be effective against disease, mortality, and leptospiruria caused by four Leptospira serovars:2,5
    • L. canicola
    • L. icterohaemorrhagiae
    • L. pomona
    • L. grippotyphosa

VACCIPURE™ FILTRATION TECHNOLOGY

  • A porous filtration membrane selectively removes extraneous proteins, salts, and solvents
  • Fewer total proteins (TP) means a more purified final product, which may reduce unwanted immune system responses such as vaccine reactions1
  • Promotes a higher level of vaccine quality
  • Same process used for Nobivac® Lepto4, Nobivac® Canine-1 DAPPv+L4, and Nobivac EDGE™ Lepto4

Nobivac EDGE™ DAPPv

The only 0.5 mL that provides protection against parainfluenza, distemper, adenovirus type 1 (hepatitis), and parvovirus in one formula.

PROVEN PROTECTION

  • The only 0.5 mL combination vaccine formula to include parainfluenza
  • Protects against all known strains of canine parvovirus (CPV), including CPV-2c3,4
  • Contains CPV-2b, one of the most prevalent field strains of parvovirus
  • High antigenic mass (titer), low passage parvovirus vaccine
  • Overrides CPV maternal antibodies in young puppies1
  • Protects against adenovirus type 1 that causes hepatitis in dogs
  • Systemic administration stimulates a strong IgG response (CPiV)1

NOBIVAC® SAFETY & QUALITY

  • Lower total protein level than other 0.5 ml vaccine options1
  • Onderstepoort-type strain in Nobivac® vaccines provides a high level of safety (CDV)1

Nobivac EDGE™ DAPPv+L4

The only 0.5 mL combo vaccine to provide parainfluenza protection in combination with four-way leptospirosis protection.

CONVENIENT COMBO PROTECTION

  • The only 0.5 mL leptospirosis vaccine to aid in the prevention of disease, mortality, and leptospiriuria caused by four Leptospira serovars2,5
  • The only 0.5 mL combination vaccine formula to include parainfluenza
  • Protects against all known strains of canine parvovirus (CPV), including CPV-2c3,4
  • Contains CPV-2b, one of the most prevalent field strains of parvovirus
  • High antigenic mass (titer), low passage parvovirus vaccine
  • Overrides CPV maternal antibodies in young puppies1
  • Systemic administration stimulates a strong IgG response (CPiV)1
  • Protects against adenovirus type 1 that causes hepatitis in dogs

NOBIVAC® SAFETY & QUALITY

  • 99% Reaction Free: out of 1,583 doses given in Clinical Impressions study1
  • Lower total protein level than other 0.5 ml vaccine options1
  • Onderstepoort-type strain in Nobivac® vaccines provides a high level of safety (CDV)1

LEPTO4 VACCIPURE™ FILTRATION TECHNOLOGY

  • A porous filtration membrane selectively removes extraneous proteins, salts, and solvents
  • Fewer total proteins (TP) means a more purified final product, which may reduce unwanted immune system responses such as vaccine reactions1
  • Promotes a higher level of vaccine quality
  • Same process used for Nobivac® Lepto4, Nobivac® Canine-1 DAPPv+L4, and Nobivac EDGE™ Lepto4







GET NOBIVAC EDGE™ : FULL SIZE PROTECTION, HALF SIZE VACCINES





Get the proven efficacy of Nobivac EDGE™ 0.5 mL for dogs of all sizes.







contact us











TECHNICAL ASSISTANCE





For technical assistance or to report a suspected adverse drug reaction, contact Merck Animal Health at 1-800-224-5318





REFERENCES:
1. Data on file, Merck Animal Health. 2. LaFleur RL, Dant JC, Wasmoen TL. Prevention of disease and mortality in vaccinated dogs following experimental challenge with virulent leptospira. J Vet Int Med, May/June 2011, Vol 25, Issue 3; 747. 3. Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther. 2008;9(2):94–101. 4. Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142 Suppl 1:S102–S108. 5. LaFleur RL, Dant JC, Wasmoen TL, et al. Prevention of leptospiremia and leptospiruria following vaccination with DAPPv + 4-way Leptospira combination vaccine. ISCAID Symposium Proceedings, October 2016, Bristol, UK.